Experiments in vivo exhibited that intratumoral delivery of these complexes to subcutaneous ovarian tumors not only significantly suppressed tumor growth and migration of tumor cells but also led to reducing CSNK2A1 mRNA and CK2α protein expression [282]. This evidence concerns the gene CSNK2A1 and neoplasm.